Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes (U01 - Clinical Trial Not Allowed)

This Notice of Funding Opportunity (NOFO) invites applications for a multisite study to comprehensively characterize ADRD relevant pathology related to cognitive impairment and dementia outcomes in persons with a history of traumatic brain injury (TBI). Investigations should elucidate the contribution of key individual (sex, age at time of injury, time since injury, social determinants of health, etc.) and injury characteristics (injury severity and frequency) to describe associations between neuropathological burden and antemortem clinicopathologic symptoms and outline the prevalence of TBI-related ADRD diagnoses, and CTE pathology in the participating brain banks. This NOFO intends to support applications that include retrospective samples, plans to acquire new brain tissue specimens, and methods to assess the antemortem symptomatology and clinical presentation. To further advance research in the area, broad sharing of clinical and neuropathological data will be a critical feature of successful applications, including the development of a digital resource for distribution and sharing of assessed neuropathological tissue.

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.